ACM
PRCT icon

Altium Capital Management’s Procept Biorobotics PRCT Stock Holding History

Altium Capital Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-81,000
Closed -$3.36M – 123
2022
Q3 		$3.36M Sell
81,000
-17,000
-17% -$678K 1.23% 33
2022
Q2 		$3.2M Buy
98,000
+50,923
+108% +$1.85M 1.28% 29
2022
Q1 		$1.65M Buy
+47,077
New +$1.13M 0.55% 64

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Altium Capital Management's PRCT Position: Q4 2022 in Review

Altium Capital Management sold out of Procept Biorobotics (PRCT) in Q4 2022, closing a stake of 81,000 shares — an estimated $3.36M sold.

Altium Capital Management first reported a position in PRCT in Q1 2022 and held it in 3 quarters. The position peaked at $3.36M in Q3 2022. 116 funds tracked by Wall St. Rank hold PRCT as of Q4 2022.

  • Altium Capital Management reported no remaining Procept Biorobotics position as of Q4 2022 after selling out during the quarter.
  • Altium Capital Management sold 81,000 Procept Biorobotics shares in Q4 2022, an estimated $3.36M.
  • Altium Capital Management first reported a position in Procept Biorobotics in Q1 2022 and held it in 3 quarters.
  • Altium Capital Management's Procept Biorobotics position peaked at $3.36M in Q3 2022.
  • 116 funds tracked by Wall St. Rank held Procept Biorobotics as of Q4 2022.

Based on Altium Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.